Cite
HARVARD Citation
Gilboa, M. et al. (2022). Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience. Journal of infectious diseases. pp. 785-792. [Online].